Demerger Spin Off Value Unlock
Expected: CurrentHIGH confidence
What: A&P Spend: Mid-teens %
“And that was the whole case of separation which would have led to this business as a standalone growing much faster than what it was in the past.”
Sanofi Consumer Healthcare India Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +13.5%StrongRe-Entry
In , Sanofi Consumer Healthcare India Ltd (Pharma - MNC bulk Drugs) is outperforming Nifty 500 with +13.5% relative strength. Fundamentals: Strong.
Sanofi Consumer Healthcare India Ltd Key Facts
- PE Ratio
- 43.4x
- Market Cap
- ₹10,972 Cr
- PAT Growth YoY
- +36%
- Revenue Growth YoY
- +32%
- OPM
- 39.0%
- RS vs Nifty 500
- +13.5%
Emerging Opportunity
What's Happening
⏳Steady earner with flat PE — waiting for re-rate catalyst
📊Debt increased 40% YoY — leverage rising
👔Promoter buying — stake up 10.9% this quarter
🌐FII stake decreased 2.3% this quarter
🏛️DII reducing — stake down 6.6%
💰Trading 47% below estimated fair value — significant discount
Earnings Acceleration Triggers
1. Demerger Spin Off Value Unlock
CurrentHIGH
2. Market Share Gains
By 2026HIGH
3. New Product Or Brand Launch
OngoingMEDIUM
Key Risks
1. Uncertainty regarding the timeline and final structure of the national OTC polic
MEDIUM2. Potential impact of raw material costs on the bottom line
LOWSector-Specific Signals
Avil Volume RankNumber 1
Allegra Value RankNumber 3
A&P Spend as % of SalesMid-teensIncreased from low single digits
HCP Reach Expansion Target2X
Key Numbers
PAT Growth YoY
+36%
Stable
Revenue YoY
+32%
Stable
Operating Margin
39.0%
+200 bps YoY
PE Ratio
43.4
Current Price
₹4,764
Dividend Yield
1.15%
Fundamental Score
65/100
Strong
3Y PAT CAGR
+21%
Market Cap
11.0K Cr
Valuation
Significantly Undervalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Sanofi Consumer Healthcare India Ltd's Earnings Accelerating?
Based on Q3 FY26 earnings • Updated Apr 19, 2026
Market Share Gains
Expected: By 2026HIGH confidence
What: Direct Retail Coverage: 2X
“So, both on the HCP side, consumer side and the retail side, efforts have been increased to make sure that our access and our reach becomes much larger.”
New Product Or Brand Launch
Expected: OngoingMEDIUM confidence
What: Product Pipeline: Allegra D
“I think one case in point was the launch of Allegra D, which just happened last year, which was one of the unique formulations that you see in the India market.”
Tam Expansion Changing Consumption
Expected: OngoingMEDIUM confidence
What: Self-medication rate: 1 in 4 consumers
“Almost 1 in every 4 consumers are self-medicating today. 15% where they ask the pharmacist. And that's a landscape that's only going to increase.”
Regulatory Approval Or License Win
Expected: FutureMEDIUM confidence
What: OTC Policy: Pending
“I think the biggest unlock will be direct consumer communication, you know, the moment OTC comes in, and then that gives us the freedom to really, again, build the category.”
Domestic sales growth of 22%
HIGH confidence
What: Domestic sales growth of 22%
“If you see the quarter for domestic sales, it grew by 22%, and you remove the recall from there. Without recall, the growth is 11%.”
What Are the Key Risks for Sanofi Consumer Healthcare India Ltd?
Earnings deceleration risks from management commentary
Uncertainty regarding the timeline and final structure of the national OTC polic
MEDIUMTrigger: The policy is still 'in the works' and its absence currently constrains direct consumer communication for certain brands.
Management view: The company is using brand extensions (like Combiflam cream) that are already allowed to speak to consumers directly.
Monitor: regulatory
Potential impact of raw material costs on the bottom line
LOWTrigger: Management noted they are 'very mindful' of the bottom line while increasing A&P spends.
Management view: Maintaining a lean and efficient independent supply chain to manage overall costs.
Monitor: commodity
What Is Sanofi Consumer Healthcare India Ltd's Management Saying?
Key quotes from recent conference calls
“So, we plan to double our doctor reach face to face. ... from where we are, we plan to double the reach to HCPs. [Initiative: HCP Reach Expansion]”
“Increasing direct retail coverage. ... And, of course, increasing our direct coverage also by 2X. [Initiative: Direct Retail Coverage]”
“So, the ANP, again, really moving from a very low single digit to mid-teens. And that was the whole case of separation. [Initiative: A&P Spend Increase]”
“As you're aware, the OTC policy is still in the works. ... so as of now, it's still in the works. [Risk (regulatory): MEDIUM]”
What Did Sanofi Consumer Healthcare India Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
₹880 crore
YoY +21%
Why: Revenue growth was driven by a 21% increase in operations and a recovery in domestic sales which grew by 22% including the impact of product recalls.
Management highlighted that without the recall impact, domestic sales growth was 11%.
EBITDA
Not Disclosed
YoY +13%Margin 37%
Why: Operating profit increased by 13% as the company focused on reigniting profitable growth and managing a lean and efficient supply chain.
The 37% margin refers to Profit from Operations as a percentage of turnover.
PAT
Not Disclosed
YoY +33%
Why: PAT growth of 33% was achieved through improved business performance and the successful relaunch of products that had been previously recalled.
The company is focusing on a 'challenger mindset' to drive differentiated reward structures and accountability.
Other Highlights
• ROCE recorded at 62.5% for the period.
• Domestic sales grew by 22% including recall recovery.
• Direct retail coverage target set to increase by 2X.
What Sector Metrics Matter for Sanofi Consumer Healthcare India Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Avil Volume Rank
Number 1
Allegra Value Rank
Number 3
A&P Spend as % of Sales
Mid-teens
YoY Increased from low single digits
Why: Strategic shift to fund growth through brand equity post-demerger.
HCP Reach Expansion Target
2X
Why: Plan to double face-to-face reach to healthcare professionals in 2026.
Direct Retail Coverage Target
2X
Why: Initiative to increase direct store presence for better visibility and range selling.
Digital HCP Reach
50,000
Why: Scaling up engagement efforts through digital channels.
Medical Representative Team Size
350
Why: Current size of the field force post-separation.
Indian Population Vitamin D Deficiency
70%
Why: Market potential indicator for the DePURA brand.
Consumer Self-Medication Rate
25%
Why: Reflects the growing trend of self-care and self-choice in healthcare.
In-India Production Share
100%
Why: Ensures independence from global supply chains and better stock control.
What Is Sanofi Consumer Healthcare India Ltd's Management Guidance?
Forward-looking targets from management
Management Tone: BULLISH
How Fast Is Sanofi Consumer Healthcare India Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +32% | +26% | Stable |
| PAT (Net Profit) | +36% | +21% | Stable |
| OPM | 39.0% | +200 bps | Stable |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 19, 2026.
Other Top Pharma - MNC bulk Drugs Stocks Beating Nifty 500
Frequently Asked Questions: Sanofi Consumer Healthcare India Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Sanofi Consumer Healthcare India Ltd's latest quarterly results?
Sanofi Consumer Healthcare India Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +36.0% (stable)
- Revenue Growth YoY: +32.4%
- Operating Margin: 39.0% (stable)
Is Sanofi Consumer Healthcare India Ltd's profit growing or declining?
Sanofi Consumer Healthcare India Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +36.0% (latest quarter)
- PAT Growth QoQ: +3.0% (sequential)
- 3-Year PAT CAGR: +20.6%
- Trend: Stable — consistent growth pattern
What is Sanofi Consumer Healthcare India Ltd's revenue growth trend?
Sanofi Consumer Healthcare India Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +32.4%
- Revenue Growth QoQ: -8.8% (sequential)
- 3-Year Revenue CAGR: +25.8%
How is Sanofi Consumer Healthcare India Ltd's operating margin trending?
Sanofi Consumer Healthcare India Ltd's operating margin is stable.
- Current OPM: 39.0%
- OPM Change YoY: +2.0% basis points
- OPM Change QoQ: +3.0% basis points
What is Sanofi Consumer Healthcare India Ltd's 3-year profit and revenue CAGR?
Sanofi Consumer Healthcare India Ltd's long-term compounding rates
- 3-Year Profit CAGR: +20.6%
- 3-Year Revenue CAGR: +25.8%
Is Sanofi Consumer Healthcare India Ltd's growth accelerating or decelerating?
Sanofi Consumer Healthcare India Ltd's earnings growth is stable with positive momentum on a sequential basis.
- YoY Acceleration: -14.0% bps
- Sequential Acceleration: -1.8% bps
What is Sanofi Consumer Healthcare India Ltd's trailing twelve month (TTM) performance?
Sanofi Consumer Healthcare India Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹258 Cr
- TTM PAT Growth: +53.6% YoY
- TTM Revenue: ₹935 Cr
- TTM Revenue Growth: +38.3% YoY
- TTM Operating Margin: 35.8%
Is Sanofi Consumer Healthcare India Ltd overvalued or undervalued?
Sanofi Consumer Healthcare India Ltd appears significantly undervalued based on our fair value analysis.
- Valuation Signal: Significantly Undervalued
- Current PE: 43.4x
- Price-to-Book: 28.5x
What is Sanofi Consumer Healthcare India Ltd's current PE ratio?
Sanofi Consumer Healthcare India Ltd's current PE ratio is 43.4x.
- Current PE: 43.4x
- Market Cap: 11.0K Cr
- Dividend Yield: 1.15%
How does Sanofi Consumer Healthcare India Ltd's valuation compare to its history?
Sanofi Consumer Healthcare India Ltd's current PE is 43.4x.
- Current PE: 43.4x
- Valuation Assessment: Significantly Undervalued
What is Sanofi Consumer Healthcare India Ltd's price-to-book ratio?
Sanofi Consumer Healthcare India Ltd's price-to-book ratio is 28.5x.
- Price-to-Book (P/B): 28.5x
- Book Value per Share: ₹167
- Current Price: ₹4764
Is Sanofi Consumer Healthcare India Ltd a fundamentally strong company?
Sanofi Consumer Healthcare India Ltd is rated Strong with a fundamental score of 64.6/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +32.4% (10% weight)
- PAT Growth YoY: +36.0% (10% weight)
- PAT Growth QoQ: +3.0% (10% weight)
- Margins stable (10% weight)
Is Sanofi Consumer Healthcare India Ltd debt free?
Sanofi Consumer Healthcare India Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹28 Cr
What is Sanofi Consumer Healthcare India Ltd's return on equity (ROE) and ROCE?
Sanofi Consumer Healthcare India Ltd's return ratios over recent years
- Dec 2024: ROCE 111.0%
Is Sanofi Consumer Healthcare India Ltd's cash flow positive?
Sanofi Consumer Healthcare India Ltd's operating cash flow is positive (Dec 2024).
- Cash from Operations (CFO): ₹439 Cr
- Free Cash Flow (FCF): ₹441 Cr
- CFO/PAT Ratio: 243% (strong cash conversion)
What is Sanofi Consumer Healthcare India Ltd's dividend yield?
Sanofi Consumer Healthcare India Ltd's current dividend yield is 1.15%.
- Dividend Yield: 1.15%
- Current Price: ₹4764
Who holds Sanofi Consumer Healthcare India Ltd shares — promoters, FII, DII?
Sanofi Consumer Healthcare India Ltd's shareholding pattern (Mar 2026)
- Promoters: 71.3%
- FII (Foreign): 2.8%
- DII (Domestic): 17.6%
- Public: 8.4%
Is promoter holding increasing or decreasing in Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 71.3% (Mar 2026)
- Previous Quarter: 71.3% (Dec 2025)
- Change: 0.00% (stable)
How long has Sanofi Consumer Healthcare India Ltd been outperforming Nifty 500?
Sanofi Consumer Healthcare India Ltd has been outperforming Nifty 500 for 2 consecutive weeks, indicating early-stage outperformance.
Is Sanofi Consumer Healthcare India Ltd a new momentum entry or an established outperformer?
Sanofi Consumer Healthcare India Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
What are the growth catalysts for Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd has 6 key growth catalysts identified from recent earnings analysis
- Demerger Spin Off Value Unlock — The separation from Sanofi allows the consumer business to fund its own growth through brand equity rather than a pharma-led prescription model.
- Market Share Gains — Doubling direct retail coverage and HCP reach is intended to capture headroom in core categories like allergy and pain.
- New Product Or Brand Launch — The company is leveraging global R&D to launch unique formulations like Allegra D for congestion.
- Tam Expansion Changing Consumption — Increasing consumer self-care and online health searches are expanding the addressable market for consumer healthcare brands.
What are the key risks in Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd has 2 key risks worth monitoring
- [MEDIUM] Uncertainty regarding the timeline and final structure of the national OTC polic — The policy is still 'in the works' and its absence currently constrains direct consumer communication for certain brands.
- [LOW] Potential impact of raw material costs on the bottom line — Management noted they are 'very mindful' of the bottom line while increasing A&P spends.
What did Sanofi Consumer Healthcare India Ltd's management say in the latest earnings call?
In Q3 FY26, Sanofi Consumer Healthcare India Ltd's management highlighted
- "So, we plan to double our doctor reach face to face. ... from where we are, we plan to double the reach to HCPs. [Initiative: HCP Reach Expansion]"
- "Increasing direct retail coverage. ... And, of course, increasing our direct coverage also by 2X. [Initiative: Direct Retail Coverage]"
- "So, the ANP, again, really moving from a very low single digit to mid-teens. And that was the whole case of separation. [Initiative: A&P Spend Increa..."
What is Sanofi Consumer Healthcare India Ltd's management guidance for growth?
Sanofi Consumer Healthcare India Ltd's management has provided the following forward guidance
- Revenue outlook: Not Given
- Margin outlook: Not Given
- Management tone: bullish
What sector-specific metrics matter most for Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd's most important sub-sector-specific KPIs from the latest concall
- Avil Volume Rank: Number 1
- Allegra Value Rank: Number 3
- A&P Spend as % of Sales: Mid-teens (YoY Increased from low single digits) — Strategic shift to fund growth through brand equity post-demerger.
- HCP Reach Expansion Target: 2X — Plan to double face-to-face reach to healthcare professionals in 2026.
- Direct Retail Coverage Target: 2X — Initiative to increase direct store presence for better visibility and range selling.
- Digital HCP Reach: 50,000 — Scaling up engagement efforts through digital channels.
Is Sanofi Consumer Healthcare India Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Sanofi Consumer Healthcare India Ltd may be worth studying
- Earnings growing at +36.0% YoY
- Valuation: appears significantly undervalued
- Cash flow is positive — CFO ₹439 Cr
What is the investment thesis for Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +32.4% YoY
- Appears significantly undervalued
- Growth catalyst: Demerger Spin Off Value Unlock
Risk Factors (Bear Case)
- Key risk: Uncertainty regarding the timeline and final structure of the national OTC polic
What is the future outlook for Sanofi Consumer Healthcare India Ltd?
Sanofi Consumer Healthcare India Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: stable
- Valuation: Significantly Undervalued
- Key Catalyst: Demerger Spin Off Value Unlock
- Key Risk: Uncertainty regarding the timeline and final structure of the national OTC polic
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.